Skip to main content
Top
Published in: Pediatric Cardiology 7/2017

Open Access 01-10-2017 | Original Article

Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia

Authors: Xiaomei Li, Yan Zhang, Haiju Liu, He Jiang, Haiyan Ge, Yi Zhang

Published in: Pediatric Cardiology | Issue 7/2017

Login to get access

Abstract

In a recently published study, we evaluated the efficacy and safety of intravenous sotalol in pediatric patients with incessant tachyarrhythmias and we have found that intravenous sotalol is effective and safe. Our dosing regimen was based on the body weight of the patients. In the US, the recommendation for intravenous sotalol dosing in pediatric patients is based on body surface area (BSA) while taking into consideration the patients’ age. The purpose of this paper is to show the correspondence of a body weight-based dosing regimen when expressed for BSA as mg/m2. We evaluated the similarity of a body weight-based dose to that calculated based on BSA using the US labeling recommendations. Of the 83 patients, 5 were newborns (age: 0–30 days), 39 infants and toddlers (age: 1–24 month), 26 young children (age: >2–6 years), 11 older children (age: 6–12 years), and 2 adolescents (age: 14 years). Each received a loading dose of 1 mg/kg intravenous sotalol administered over 10 min followed by a maintenance dose of 4.5 mg/kg/day. There was a close correlation between the sotalol loading doses calculated based on body weight and BSA across the entire age range (r = 0.977, p < 0.001). In most of the age groups, the body weight-based loading doses were lower or equal to the BSA-based doses. Only in the adolescents were the body weight-based doses higher. The maintenance doses given in our study were significantly higher than the BSA-based dose in newborns: 75 ± 6 versus 53 ± 8 mg/m2, p < 0.05; infants/toddlers: 88 ± 14 versus 77 ± 7 mg/m2, p < 0.001; younger children: 113 ± 12 versus 85 mg/m2, p < 0.001; older children: 123 ± 16 versus 85 mg/m2, p < 0.01; and adolescents 157 ± 30 versus 85.5 mg/m2. Despite the rapid administration of the loading dose and the increased maintenance doses, our body weight-based dosing regimen was safe. Only one newborn had significant adverse event (AV block) that resolved spontaneously after discontinuation of the infusion.
Literature
1.
go back to reference Rao SO, Boramanand NK, Burton DA, Perry JC (2009) Atrial tachycardias in young adults and adolescents with congenital heart disease: conversion using single dose oral sotalol. Int J Cardiol 136:253–257CrossRefPubMed Rao SO, Boramanand NK, Burton DA, Perry JC (2009) Atrial tachycardias in young adults and adolescents with congenital heart disease: conversion using single dose oral sotalol. Int J Cardiol 136:253–257CrossRefPubMed
2.
go back to reference Miyazaki A, Ohuchi H, Kurosaki K, Kamakura S, Yagihara T, Yamada O (2008) Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease. Circ J 72:1998–2003CrossRefPubMed Miyazaki A, Ohuchi H, Kurosaki K, Kamakura S, Yagihara T, Yamada O (2008) Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease. Circ J 72:1998–2003CrossRefPubMed
3.
go back to reference Knudson JD, Cannon BC, Kim JJ, Moffett BS (2011) High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias. Pediatr Cardiol 32:896–903CrossRefPubMed Knudson JD, Cannon BC, Kim JJ, Moffett BS (2011) High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias. Pediatr Cardiol 32:896–903CrossRefPubMed
4.
go back to reference Läer S, Elshoff JP, Meibohm B, Weil J, Mir TS, Zhang W, Hulpke-Wette M (2005) Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol 46:1322–1330CrossRefPubMed Läer S, Elshoff JP, Meibohm B, Weil J, Mir TS, Zhang W, Hulpke-Wette M (2005) Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol 46:1322–1330CrossRefPubMed
5.
go back to reference Pfammatter JP, Paul T, Lehmann C, Kallfelz HC (1995) Efficacy and proarrhythmia of oral sotalol in pediatric patients. J Am Coll Cardiol 26:1002–1007CrossRefPubMed Pfammatter JP, Paul T, Lehmann C, Kallfelz HC (1995) Efficacy and proarrhythmia of oral sotalol in pediatric patients. J Am Coll Cardiol 26:1002–1007CrossRefPubMed
6.
go back to reference Tanel RE, Walsh EP, Lulu JA, Saul JP (1995) Sotalol for refractory arrhythmias in pediatric and young adult patients: initial efficacy and long-term outcome. Am Heart J 130:791–797CrossRefPubMed Tanel RE, Walsh EP, Lulu JA, Saul JP (1995) Sotalol for refractory arrhythmias in pediatric and young adult patients: initial efficacy and long-term outcome. Am Heart J 130:791–797CrossRefPubMed
9.
go back to reference Campbell TJ, Gavaghan TP, Morgan JJ (1985) Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. Br Heart J 54:86–90CrossRefPubMedPubMedCentral Campbell TJ, Gavaghan TP, Morgan JJ (1985) Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. Br Heart J 54:86–90CrossRefPubMedPubMedCentral
10.
go back to reference Fu GS, Wille B (1999) Hemodynamic effects and electrophysiological effects of sotalol to patients with fatal ventricular arrhythmia. Chin J Inter Med 38:30–32 Fu GS, Wille B (1999) Hemodynamic effects and electrophysiological effects of sotalol to patients with fatal ventricular arrhythmia. Chin J Inter Med 38:30–32
11.
go back to reference Joseph AP, Ward MR (2000) A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. Ann Emerg Med 36:1–9CrossRefPubMed Joseph AP, Ward MR (2000) A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. Ann Emerg Med 36:1–9CrossRefPubMed
12.
go back to reference Reisinger J, Gatterer E, Heinze G, Wiesinger K, Zeindlhofer E, Gattermeier M, Poelzl G, Kratzer H, Ebner A, Hohenwallner W, Lenz K, Slany J, Kuhn P (1998) Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 81:1450–1454CrossRefPubMed Reisinger J, Gatterer E, Heinze G, Wiesinger K, Zeindlhofer E, Gattermeier M, Poelzl G, Kratzer H, Ebner A, Hohenwallner W, Lenz K, Slany J, Kuhn P (1998) Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 81:1450–1454CrossRefPubMed
13.
go back to reference Thomas SP, Guy D, Wallace E, Crampton R, Kijvanit P, Eipper V, Ross DL, Cooper MJ (2004) Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial. Am Heart J 147:E3. doi:10.1016/S0002-8703(03)00526-X CrossRefPubMed Thomas SP, Guy D, Wallace E, Crampton R, Kijvanit P, Eipper V, Ross DL, Cooper MJ (2004) Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial. Am Heart J 147:E3. doi:10.​1016/​S0002-8703(03)00526-X CrossRefPubMed
14.
go back to reference Vos MA, Golitsyn SR, Stangl K, Ruda MY, Van Wijk LV, Harry JD, Perry KT, Touboul P, Steinbeck G, Wellens HJ (1998) Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The ibutilide/sotalol comparator study group. Heart 79:568–575CrossRefPubMedPubMedCentral Vos MA, Golitsyn SR, Stangl K, Ruda MY, Van Wijk LV, Harry JD, Perry KT, Touboul P, Steinbeck G, Wellens HJ (1998) Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The ibutilide/sotalol comparator study group. Heart 79:568–575CrossRefPubMedPubMedCentral
16.
go back to reference Somberg JC, Preston RA, Ranade V, Molnar J (2010) Developing a safe intravenous sotalol dosing regimen. Am J Ther 17:365–372PubMed Somberg JC, Preston RA, Ranade V, Molnar J (2010) Developing a safe intravenous sotalol dosing regimen. Am J Ther 17:365–372PubMed
17.
go back to reference Barbey JT, Sale ME, Woosley RL, Shi J, Melikian AP, Hinderling PH (1999) Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects. Clin Pharmacol Ther 66:91–99CrossRefPubMed Barbey JT, Sale ME, Woosley RL, Shi J, Melikian AP, Hinderling PH (1999) Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects. Clin Pharmacol Ther 66:91–99CrossRefPubMed
18.
go back to reference Somberg JC, Preston RA, Ranade V, Molnar J (2010) QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol. Cardiology 116:219–225CrossRefPubMed Somberg JC, Preston RA, Ranade V, Molnar J (2010) QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol. Cardiology 116:219–225CrossRefPubMed
Metadata
Title
Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia
Authors
Xiaomei Li
Yan Zhang
Haiju Liu
He Jiang
Haiyan Ge
Yi Zhang
Publication date
01-10-2017
Publisher
Springer US
Published in
Pediatric Cardiology / Issue 7/2017
Print ISSN: 0172-0643
Electronic ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-017-1683-9

Other articles of this Issue 7/2017

Pediatric Cardiology 7/2017 Go to the issue